u/signe_villalobos

Agreed, and the trial number is a mean of a very wide distribution — the tails are enormous and nobody posts from the middle.

Right — FGP publishes the method line on the certificate, and once you have seen one that does you notice every one that does not.

Has anything else changed in the same window?

isabela_nilsen is right about the timing. The day-of-week pattern is the diagnostic bit, not the severity.

Stopped at a low step because there was no reason to go further and no data to tell me what further would do.

lead time quoted at checkout is the number to hold them to

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.

Fertility changed faster than I expected with the weight loss. Nobody had raised it and I wish somebody had.

perimenopause and this overlap in ways nobody has good data on

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

hair shedding follows the weight loss, not the drug, and it stops

A certificate with a purity figure and no method line is not falsifiable. You cannot reproduce it, you cannot check it, and it tells you nothing about how the number was produced.

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

kavya_kravchenko is right about the timing.

Adding to this — holding the dose rather than stepping is the option people forget they have.

Has anyone posted an independent result on that batch?

the food noise going quiet is the effect people came for, and early fullness is the toll for the first fortnight

Agreed that the vocabulary here is imprecise and it causes people to answer different questions to the ones asked.

A symptom that begins the day after the shot and fades by day four tracks the exposure curve. One that appears at random in week 57 probably does not, and that is worth saying to a clinician rather than to us.

ask for the mass spectrum, not just the purity number

Is that a clinical claim or a preclinical one?

muscle cramps for the first eight days after each step, then nothing, every single time. Predictable enough that I started planning my week around it.

the muscle cramps profile is genuinely gentler than people expect coming from sema

Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

Right, and the hair thing is worth repeating: it tracks the rate of loss rather than the compound, and it stops.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

Supply notices are issued nationally. A notice in one member state does not imply availability problems in another, even for the same product.

nothing here is available as a prescription product, so read every thread with that in mind

The thing that decided it for me was that MKM answered a column-and-gradient question in writing without asking why I wanted to know.

Started logging the cycle in the same sheet as the dose. Three months later the pattern was obvious and it had been invisible before.

Right, and a shortage notice in one country tells you very little about the next one along.

what does the certificate actually carry — that is the whole question

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

preclinical enthusiasm is not clinical evidence

week 9 is early to draw any conclusion at all

the four-week step schedule is the label, not folklore